National Institute for Cellular Biotechnology, School of Biotechnology, Dublin City University, Dublin 9, Ireland.
BGI Education Centre, University of Chinese Academy of Sciences, Shenzhen, 518083, China.
Sci Rep. 2020 Feb 17;10(1):2778. doi: 10.1038/s41598-020-59368-7.
With a five-year survival rate of 9%, pancreatic ductal adenocarcinoma (PDAC) is the deadliest of all cancers. The rapid mortality makes PDAC difficult to research, and inspires a resolve to create reliable, tractable cellular models for preclinical cancer research. Organoids are increasingly used to model PDAC as they maintain the differentiation status, molecular and genomic signatures of the original tumour. In this paper, we present novel methodologies and experimental approaches to develop PDAC organoids from PDX tumours, and the simultaneous development of matched primary cell lines. Moreover, we also present a method of recapitulating primary cell line cultures to organoids (CLOs). We highlight the usefulness of CLOs as PDAC organoid models, as they maintain similar transcriptomic signatures as their matched patient-derived organoids and patient derived xenografts (PDX)s. These models provide a manageable, expandable in vitro resource for downstream applications such as high throughput screening, functional genomics, and tumour microenvironment studies.
胰腺癌(PDAC)的五年存活率为 9%,是所有癌症中致死率最高的。这种快速的死亡率使得 PDAC 难以研究,也激发了人们创造可靠、可处理的细胞模型来进行临床前癌症研究的决心。类器官越来越多地被用于模拟 PDAC,因为它们保持了原始肿瘤的分化状态、分子和基因组特征。在本文中,我们提出了从 PDX 肿瘤中开发 PDAC 类器官和同时开发匹配的原代细胞系的新方法和实验方法。此外,我们还提出了一种将原代细胞系培养物再生成类器官(CLO)的方法。我们强调了 CLO 作为 PDAC 类器官模型的有用性,因为它们与匹配的患者来源的类器官和患者来源的异种移植物(PDX)保持相似的转录组特征。这些模型为下游应用提供了可管理、可扩展的体外资源,例如高通量筛选、功能基因组学和肿瘤微环境研究。